Mostrar el registro sencillo del ítem
dc.contributor.author
González, Claudio Daniel
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Alvariñas, Jorge
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Gonzalez Bagnes, Maria Florencia
dc.contributor.author
Di Girolamo, Guillermo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2021-01-18T15:05:54Z
dc.date.issued
2019-03-13
dc.identifier.citation
González, Claudio Daniel; Alvariñas, Jorge; Gonzalez Bagnes, Maria Florencia; Di Girolamo, Guillermo; Metformin and pregnancy outcomes: Evidence gaps and unanswered questions; Bentham Science Publishers; Current Clinical Pharmacology; 14; 1; 13-3-2019; 54-60
dc.identifier.issn
1574-8847
dc.identifier.uri
http://hdl.handle.net/11336/122844
dc.description.abstract
Background: Metformin is sometimes used as an alternative to insulin in gestational diabetes mellitus (GDM). It is also used to achieve ovulation in polycystic ovary syndrome (PCOS). Pre-natal exposure to metformin results from its continuation after a successful ovulation in women with PCOS, its maintenance in women with pre-gestational diabetes or the installation of metformin in GDM. Little is known about the potential consequences of metformin exposure on pregnancy outcomes and offspring development. The aim of this review is to summarize the metformin effects on pregnancy outcomes and offspring development. Gaps in the available evidence and unanswered questions are also discussed. Methods: A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed, EMBASE and SCIELO databases through 1995 first semester. Results: Several factors limit the effect of metformin on embryos. In contrast, placental transport of metformin is effective allowing for a higher fetal exposure; the impact of this finding remains unclear. It seems that the interruption of metformin after a pregnancy diagnosis in women with PCOS is not associated with a higher miscarriage risk and it continuation does not seem to impair the maternal metabolic prognosis or prevent emerging GDM. Conclusions: It seems to have no sense to prolong the use of metformin after a pregnancy diagnosis in women with PCOS. Patients with GDM may be treated with metformin under on judicious basis, and a careful attachment to clinical guidelines and regulations is recommended. The long-term effects of pre-natal exposure to metformin on the offspring remain uncertain.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Bentham Science Publishers
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
GESTATIONAL DIABETES MELLITUS
dc.subject
HYPERTENSION
dc.subject
METFORMIN
dc.subject
POLYCYSTIC OVARY SYNDROME
dc.subject
PREECLAMPSIA
dc.subject
PREGNANCY OUTCOMES
dc.subject.classification
Endocrinología y Metabolismo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Metformin and pregnancy outcomes: Evidence gaps and unanswered questions
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-01-13T18:51:45Z
dc.identifier.eissn
2212-3938
dc.journal.volume
14
dc.journal.number
1
dc.journal.pagination
54-60
dc.journal.pais
Emiratos Árabes Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: González, Claudio Daniel. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacologia; Argentina
dc.description.fil
Fil: Alvariñas, Jorge. Sociedad Argentina de Diabetes; Argentina
dc.description.fil
Fil: Gonzalez Bagnes, Maria Florencia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
dc.description.fil
Fil: Di Girolamo, Guillermo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Farmacologia; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini".; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title
Current Clinical Pharmacology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/168564/article
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/1574884714666181224151116
Archivos asociados